Live Stock Coverage: Omeros Corporation’s Stock Is Buy After Today’s Big Increase

Live Stock Coverage: Omeros Corporation's Stock Is Buy After Today's Big Increase

The stock of Omeros Corporation (NASDAQ:OMER) is a huge mover today! The stock increased 3.91% or $0.48 on November 23, hitting $12.75. About 829,590 shares traded hands. Omeros Corporation (NASDAQ:OMER) has declined 7.14% since April 22, 2016 and is downtrending. It has underperformed by 12.55% the S&P500.
The move comes after 7 months positive chart setup for the $512.90 million company. It was reported on Nov, 24 by We have $13.26 PT which if reached, will make NASDAQ:OMER worth $20.52 million more.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on March, 6. They expect $-0.44 earnings per share, up 2.22% or $0.01 from last year’s $-0.45 per share. After $-0.26 actual earnings per share reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 69.23% negative EPS growth.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Out of 6 analysts covering Omeros (NASDAQ:OMER), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Omeros has been the topic of 12 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, November 10 by Needham. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Monday, August 10 by TH Capital. The rating was maintained by WBB Securities with “Strong Buy” on Tuesday, August 18. Cowen & Co maintained the shares of OMER in a report on Tuesday, August 18 with “Outperform” rating. The stock of Omeros Corporation (NASDAQ:OMER) has “Outperform” rating given on Wednesday, November 16 by Wedbush. The rating was initiated by Roth Capital with “Buy” on Monday, August 10. Needham maintained the shares of OMER in a report on Monday, August 31 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, June 3. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by Needham on Wednesday, November 11.

According to Zacks Investment Research, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.”

Insitutional Activity: The institutional sentiment increased to 1.43 in 2016 Q2. Its up 0.66, from 0.77 in 2016Q1. The ratio increased, as 15 funds sold all Omeros Corporation shares owned while 32 reduced positions. 13 funds bought stakes while 23 increased positions. They now own 19.91 million shares or 14.90% more from 17.33 million shares in 2016Q1.
Alliancebernstein Limited Partnership reported 54,000 shares or 0% of all its holdings. Blackrock Inv Mngmt Llc holds 154,233 shares or 0% of its portfolio. Mutual Of America Cap Management holds 0.03% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 115,371 shares. Deutsche Commercial Bank Ag accumulated 11,910 shares or 0% of the stock. Blackrock Advsr Lc holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 17,415 shares. Millennium Mngmt Ltd accumulated 15,362 shares or 0% of the stock. First Republic Inv Management holds 0.01% or 53,000 shares in its portfolio. The New York-based Rtw Invs Limited Liability has invested 1.89% in Omeros Corporation (NASDAQ:OMER). Bessemer Gru Inc holds 0% or 1,286 shares in its portfolio. Natl Bank Of America De has 0% invested in the company for 69,311 shares. Da Davidson And has 262,522 shares for 0.08% of their US portfolio. Blackrock Fund accumulated 0% or 1.47 million shares. Ladenburg Thalmann Serv accumulated 1,770 shares or 0% of the stock. Bnp Paribas Arbitrage last reported 0% of its portfolio in the stock. Invesco Limited reported 80,525 shares or 0% of all its holdings.

Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 4 selling transactions for $574,464 net activity. $183,826 worth of Omeros Corporation (NASDAQ:OMER) was sold by Kelbon Marcia S. on Monday, August 15. Another trade for 3,000 shares valued at $34,557 was made by Cable Thomas J. on Friday, August 12.

Another recent and important Omeros Corporation (NASDAQ:OMER) news was published by which published an article titled: “Competitive Results May Affect Omeros Corporation” on November 23, 2016.

OMER Company Profile

Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The Company’s PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment